It’s time for our weekly roundup of biotech news around the world.
- • The New York Times delves into the thorny issue of India and China’s rise in biotech drug manufacturing, which threatens to lower the price of blockbuster drugs such as Herceptin, Avastin and Enbrel. As patients in developing and middle-income countries cheer, Western drug companies and diplomats are crying foul.
- • UK biotechs are choosing to run clinical trials in “half the time and one tenth of the cost” in Russia, according to This is Money. Backers include the Kremlin, which is eager to establish Russia as a leading centre for pharma R&D.
- • Turkey’s continuing growth is creating opportunities in the biotech and energy sectors, says the head of one of the country’s leading business conglomerates. (via Citywire)
